Globus Medical, Inc. (GMED) Key Statistics & Metrics

Globus Medical, Inc. (GMED) has an ST Score of 66.7 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate GMED a Buy, with a price target of $95.13 (+20.5% vs the current price). Our ST Score grades it B (66.7/100). The ST Score is a data-driven signal, not a recommendation.

Valuation D, Profitability A, Financial Strength A, Momentum C, Growth B+, Forecast B-, Sentiment A+.

Globus Medical, Inc. (GMED) earns a valuation grade of D, measured against Medical - Devices peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Globus Medical, Inc. (GMED) earns a growth grade of B+, measured against Medical - Devices peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Globus Medical, Inc. (GMED) earns a profitability grade of A, measured against Medical - Devices peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Globus Medical, Inc. (GMED) earns a financial strength grade of A, measured against Medical - Devices peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Globus Medical, Inc. (GMED) is $95.13 from 36 analysts, which is +20.5% versus the recent price of $78.96.

Globus Medical, Inc. (GMED) has a Piotroski F-Score of 7 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.